Pathway-enrichment analyses showed that the active components of ARC could treat GA by regulating signaling pathways such as prostate cancer (hsa05215), C-type lectin receptor signaling pathway (hsa04625), TNF signaling pathway (hsa04668) and endocrine resistance (hsa01522). This evidence concerns the gene CLEC4D and Familial prostate cancer.